◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › TENX

Tenax Therapeutics, Inc. (TENX) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-10

Tenax Therapeutics, Inc. (TENX) operates in the Biotechnology industry and is headquartered in Chapel Hill, United States with about 14 employees. Its market capitalization is roughly $486 million. In the fiscal year ended 2025-12-31, TENX reported $0M in revenue and ($53M) in net income.

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.

Interactive charts & full statements →

TENX Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($56M)($20M)($8M)($11M)
Net Income($53M)($18M)($8M)($11M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TENX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($17M)($16M)($17M)($12M)($11M)
Net Income($16M)($16M)($16M)($11M)($10M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TENX Free Cash Flow History

TENX Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$104M$97M$12M$3M
Total Liabilities$7M$5M$4M$2M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TENX viewer.

Other Companies in Biotechnology

← TENBAll stocksTEO →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.